ZNF860: A Potential Drug Target and Biomarker (G344787)

Target Name: ZNF860

NCBI ID: G344787

ZNF860

Other Name(s): zinc finger protein 860 | ZN860_HUMAN | Zinc finger protein 860

ZNF860: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF860, a specific ZFP, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, ZNF860 has been shown to be involved in various signaling pathways, including cell growth, apoptosis, and angiogenesis. It has been shown to promote the growth and survival of cancer cells and has been used as a potential biomarker for cancer diagnosis and treatment.

ZNF860 is a 21-kDa protein that contains 10 zinc fingers and is characterized by its highly conserved sequence and structure. It is expressed in various tissues and cells, including brain, pancreas, heart, and blood vessels. ZNF860 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion.

In neurodegenerative diseases, ZNF860 has been linked to the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that overexpression of ZNF860 can exacerbate neurodegenerate symptoms, while inhibition of its function has been shown to protect against neurodegeneration.

In autoimmune disorders, ZNF860 has been implicated in the development and maintenance of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that ZNF860 is involved in the regulation of immune cell function and that dysregulation of its function can contribute to the development of autoimmune diseases.

Despite its potential as a drug target and biomarker, ZNF860 has not yet been fully characterized and its role in various diseases is not well understood. To further explore the function of ZNF860, researchers have performed various experiments, including RNA sequencing, gene knockout, and biochemical assays.

One of the most promising approaches to studying ZNF860 is to use small molecules as drugs that can modulate its function. Many small molecules have been shown to interact with ZNF860 and have the potential to be developed into drugs. For example, inhibitors of the zinc finger domain of ZNF860 have been shown to be effective in reducing the growth and survival of cancer cells.

In addition to its potential as a drug, ZNF860 is also a potential biomarker for various diseases. Its highly conserved structure and function make it an attractive candidate for use as a diagnostic or therapeutic target. For example, ZNF860 has been shown to be expressed in various tissues and cells and can be used as a biomarker for cancer diagnosis and treatment.

In conclusion, ZNF860 is a promising drug target and biomarker that has the potential to improve the treatment of various diseases. Further research is needed to fully understand its function and its potential as a drug and biomarker. By investigating the effects of small molecules on ZNF860 function, researchers may be able to develop new treatments for a variety of diseases.

Protein Name: Zinc Finger Protein 860

Functions: May be involved in transcriptional regulation

The "ZNF860 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF860 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets